Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

Phase 2 Completed 20 enrolled Karolinska University Hospital Schering Nordiska AB · collab

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This is a Phase II trial to study the safety and tolerability of subcutaneous alemtuzumab administered without dose escalation to patients with advanced B-cell chronic lymphocytic leukemia (B-CLL).

Timeline

Start: 2003-04
Primary completion: —
Completion: 2006-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Alemtuzumab	Monoclonal antibody	—	Subcutaneous

Study to Evaluate the Safety of Subcutaneous Alemtuzumab in Patients With B-Cell Chronic Lymphocytic Leukemia

Summary

Timeline

Drugs

Indications